Conference
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases
Authors
Clemons M; Stober C; Mates M; Joy AA; Robinson A; Hilton J; Blanchette P; Aseyev O; Pond G; Fergusson D
Volume
30
Publisher
OXFORD UNIV PRESS
Publication Date
May 1, 2019
Name of conference
ESMO Breast Cancer
Conference place
Berlin, GERMANY
Conference start date
May 2, 2019
Conference end date
May 4, 2019
Conference proceedings
ANNALS OF ONCOLOGY
ISSN
0923-7534